Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 59, showing 10 Applications out of 584 total, starting on record 71, ending on 80

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

71.

ECCT/25/03/03   ALIM STUDY
    Evaluating the safety and efficacy of Imatinib in combination with Artemether and Lumefantrine for the treatment of Uncomplicated Malaria: a three-part trial.   
Principal Investigator(s)
1. Dr. QUENTIN AWORI
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
27-10-2025 View

72.

ECCT/25/03/01   MK-5684_MSD (mCRPC)
     A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)    
Principal Investigator(s)
1. PROF MANSOOR NOORALI SALEH
Site(s) in Kenya
AGA KHAN UNIVERSITY HOSPITAL NAIROBI
 
20-05-2025 View

73.

ECCT/25/02/11   Extended Dosing OCV Trial
    A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya   
Principal Investigator(s)
1. Samuel Kariuki
Site(s) in Kenya
MMM MUKURU HEALTH CENTRE
 
16-07-2025 View

74.

ECCT/25/02/10   PrEP My Way II
    PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP
 
17-06-2025 View

75.

ECCT/25/02/09   DASH II Study
    Diagnostic Access to Self-Care & Health Services in Low- and Middle-Income Countries (DASH) – Phase II Study   
Principal Investigator(s)
1. ELIZABETH ANNE BUKUSI
Site(s) in Kenya
Migori County
 
23-05-2025 View

76.

ECCT/25/02/08   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Valentine Chepkorir Sing’oei
Site(s) in Kenya
1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
 
06-03-2025 View

77.

ECCT/25/02/07   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI-RCTP (Kisumu county)
 
13-03-2025 View

78.

ECCT/25/02/06   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
06-03-2025 View

79.

ECCT/25/02/05   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Irene Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute, Kisumu County Referral Hospital (Kisumu county)
 
07-03-2025 View

80.

ECCT/25/02/04   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. CREA-N Machakos Level 5 Hospital Site (Machakos county)
 
06-03-2025 View